ofloxacin has been researched along with lidocaine in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 10 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Fang, L; Kang, J; Wang, E; Yang, X; Yin, XB | 1 |
| Aberer, W; Arbab, E; Grims, R; Komericki, P; Kränke, B | 1 |
| Chun, IK; Gwak, HS; Song, YH | 1 |
| Bogomolov, MS; Slobodianiuk, VV | 1 |
| Balins'ka, MI; Biliaieva, OO; Iemets', VV; Korzhyk, NP; Myronov, OM | 1 |
| Bodiwala, K; Kalyankar, G; Marolia, B; Patel, Y; Prajapati, P; Shah, S | 1 |
1 review(s) available for ofloxacin and lidocaine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
17 other study(ies) available for ofloxacin and lidocaine
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Short-capillary electrophoresis with electrochemiluminescence detection using porous etched joint for fast analysis of lidocaine and ofloxacin.
Topics: Electrophoresis, Capillary; Lidocaine; Luminescence; Ofloxacin | 2004 |
Tryptase as severity marker in drug provocation tests.
Topics: Acetaminophen; Adolescent; Adult; Aspirin; Diclofenac; Drug Hypersensitivity; Female; Humans; Lidocaine; Male; Mefenamic Acid; Middle Aged; Ofloxacin; Penicillins; Prospective Studies; Serine Endopeptidases; Tryptases | 2006 |
The effects of terpenes on the permeation of lidocaine and ofloxacin from moisture-activated patches.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Acrylic Resins; Adjuvants, Pharmaceutic; Administration, Cutaneous; Animals; beta-Cyclodextrins; Biological Availability; Cellulose; Cyclohexanols; Cyclohexenes; Drug Delivery Systems; Eucalyptol; Excipients; Hydrogels; In Vitro Techniques; Lidocaine; Limonene; Male; Maleates; Menthol; Mice; Mice, Hairless; Monoterpenes; Ofloxacin; Polyethylenes; Polysorbates; Skin Absorption; Terpenes | 2009 |
[Treatment of trophic ulsers of different etiology].
Topics: Adult; Anesthetics, Local; Anti-Infective Agents, Local; Arteriosclerosis Obliterans; Bacteria; Diabetic Foot; Drug Combinations; Foot Ulcer; Humans; Lidocaine; Male; Middle Aged; Occlusive Dressings; Ofloxacin; Ointments; Pain Measurement; Treatment Outcome; Venous Insufficiency; Wound Healing | 2013 |
[Role of enterosorbents in treatment of complicated varicose disease].
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Heme; Humans; Injections, Intravenous; Lidocaine; Male; Microcirculation; Middle Aged; Ofloxacin; Ointments; Secondary Prevention; Silicones; Sorption Detoxification; Treatment Outcome; Varicose Ulcer; Varicose Veins; Venous Insufficiency | 2014 |
Simultaneous Estimation of Ofloxacin, Clotrimazole, and Lignocaine Hydrochloride in Their Combined Ear-Drop Formulation by Two Spectrophotometric Methods.
Topics: Chemistry, Pharmaceutical; Clotrimazole; Lidocaine; Ofloxacin; Pharmaceutical Solutions; Spectrophotometry | 2017 |